Arrowhead
The deal gives Arrowhead access to technologies developed by Novartis, a license to Alnylam intellectual property, and a pipeline of three preclinical RNAi drug candidates.
The disease is characterized by the accumulation of a mutant protein in the liver, leading to fibrosis, cirrhosis, and potentially cancer.
The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.
The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.
The studies will test Arrowhead's drug in combination with one of two direct-acting antiviral therapies.
Dec 3, 2014
Nov 26, 2014
Nov 18, 2014
Nov 6, 2014
Oct 16, 2014
Oct 9, 2014
Aug 21, 2014
Aug 14, 2014
Aug 14, 2014
Jul 17, 2014
Jun 19, 2014
Jun 19, 2014
Apr 3, 2014
Mar 27, 2014
Mar 27, 2014
Mar 6, 2014
Feb 20, 2014
Feb 6, 2014